Cognitive Function in a Randomized Trial of Evolocumab von Giugliano, Robert P, Mach, François, Zavitz, Kenton, Kurtz, Christopher, Im, Kyungah, Kanevsky, Estella, Schneider, Jingjing, Wang, Huei, Keech, Anthony, Pedersen, Terje R, Sabatine, Marc S, Sever, Peter S, Robinson, Jennifer G, Honarpour, Narimon, Wasserman, Scott M, Ott, Brian R

Volltext

Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia von Stein, Evan A, Honarpour, Narimon, Wasserman, Scott M, Xu, Feng, Scott, Rob, Raal, Frederick J

Volltext

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial von Raal, Frederick J, Prof, Honarpour, Narimon, MD, Blom, Dirk J, MD, Hovingh, G Kees, MD, Xu, Feng, MS, Scott, Rob, MD, Wasserman, Scott M, MD, Stein, Evan A, Prof

Volltext

A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk von Kiyosue, Arihiro, MD, PhD, Honarpour, Narimon, MD, PhD, Kurtz, Christopher, MD, Xue, Allen, PhD, Wasserman, Scott M., MD, Hirayama, Atsushi, MD, PhD

Volltext

Inflammatory and Cholesterol Risk in the FOURIER Trial von Bohula, Erin A, Giugliano, Robert P, Leiter, Lawrence A, Verma, Subodh, Park, Jeong-Gun, Sever, Peter S, Lira Pineda, Armando, Honarpour, Narimon, Wang, Huei, Murphy, Sabina A, Keech, Anthony, Pedersen, Terje R, Sabatine, Marc S

Volltext

Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk: Primary Results From the Pha... von Hirayama, Atsushi, Honarpour, Narimon, Yoshida, Masayuki, Yamashita, Shizuya, Huang, Fannie, Wasserman, Scott M., Teramoto, Tamio

Volltext

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S] von Raal, Frederick J., Giugliano, Robert P., Sabatine, Marc S., Koren, Michael J., Blom, Dirk, Seidah, Nabil G., Honarpour, Narimon, Lira, Armando, Xue, Allen, Chiruvolu, Padmaja, Jackson, Simon, Di, Mei, Peach, Matthew, Somaratne, Ransi, Wasserman, Scott M., Scott, Rob, Stein, Evan A.

Volltext

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial von Sabatine, Marc S., MD, MPH, Giugliano, Robert P., MD, SM, Keech, Anthony, MD, Honarpour, Narimon, MD, PhD, Wang, Huei, PhD, Liu, Thomas, PhD, Wasserman, Scott M., MD, Scott, Robert, MD, Sever, Peter S., MD, Pedersen, Terje R., MD

Volltext

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset ana... von Raal, Frederick J, Prof, Hovingh, G Kees, PhD, Blom, Dirk, MD, Santos, Raul D, Prof, Harada-Shiba, Mariko, Prof, Bruckert, Eric, Prof, Couture, Patrick, MD, Soran, Handrean, Prof, Watts, Gerald F, Prof, Kurtz, Christopher, MD, Honarpour, Narimon, MD, Tang, Lihua, PhD, Kasichayanula, Sree, PhD, Wasserman, Scott M, MD, Stein, Evan A, Prof

Volltext

Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure von Wirtz, Heidi S, Sheer, Richard, Honarpour, Narimon, Casebeer, Adrianne W, Simmons, Jeff D, Kurtz, Christopher E, Pasquale, Margaret K, Globe, Gary

Volltext

Apoptosis in neural development and disease von NIJHAWAN, D, HONARPOUR, N, XIAODONG WANG

Volltext

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure von Teerlink, John R, Diaz, Rafael, Felker, G. Michael, McMurray, John J.V, Metra, Marco, Solomon, Scott D, Adams, Kirkwood F, Anand, Inder, Arias-Mendoza, Alexandra, Biering-Sørensen, Tor, Böhm, Michael, Bonderman, Diana, Cleland, John G.F, Corbalan, Ramon, Crespo-Leiro, Maria G, Dahlström, Ulf, Echeverria, Luis E, Fang, James C, Filippatos, Gerasimos, Fonseca, Cândida, Goncalvesova, Eva, Goudev, Assen R, Howlett, Jonathan G, Lanfear, David E, Li, Jing, Lund, Mayanna, Macdonald, Peter, Mareev, Viacheslav, Momomura, Shin-ichi, O’Meara, Eileen, Parkhomenko, Alexander, Ponikowski, Piotr, Ramires, Felix J.A, Serpytis, Pranas, Sliwa, Karen, Spinar, Jindrich, Suter, Thomas M, Tomcsanyi, Janos, Vandekerckhove, Hans, Vinereanu, Dragos, Voors, Adriaan A, Yilmaz, Mehmet B, Zannad, Faiez, Sharpsten, Lucie, Legg, Jason C, Varin, Claire, Honarpour, Narimon, Abbasi, Siddique A, Malik, Fady I, Kurtz, Christopher E

Volltext

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease von O’Donoghue, Michelle L., Rosenson, Robert S., Gencer, Baris, López, J. Antonio G., Lepor, Norman E., Baum, Seth J., Stout, Elmer, Gaudet, Daniel, Knusel, Beat, Kuder, Julia F., Ran, Xinhui, Murphy, Sabina A., Wang, Huei, Wu, You, Kassahun, Helina, Sabatine, Marc S.

Volltext

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis von Giugliano, Robert P., Pedersen, Terje R., Saver, Jeffrey L., Sever, Peter S., Keech, Anthony C., Bohula, Erin A., Murphy, Sabina A., Wasserman, Scott M., Honarpour, Narimon, Wang, Huei, Lira Pineda, Armando, Sabatine, Marc S.

Volltext

Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER von Sabatine, Marc S, De Ferrari, Gaetano M, Giugliano, Robert P, Huber, Kurt, Lewis, Basil S, Ferreira, Jorge, Kuder, Julia F, Murphy, Sabina A, Wiviott, Stephen D, Kurtz, Christopher E, Honarpour, Narimon, Keech, Anthony C, Sever, Peter S, Pedersen, Terje R

Volltext

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes:... von Sabatine, Marc S, Leiter, Lawrence A, Wiviott, Stephen D, Giugliano, Robert P, Deedwania, Prakash, De Ferrari, Gaetano M, Murphy, Sabina A, Kuder, Julia F, Gouni-Berthold, Ioanna, Lewis, Basil S, Handelsman, Yehuda, Pineda, Armando Lira, Honarpour, Narimon, Keech, Anthony C, Sever, Peter S, Pedersen, Terje R

Volltext

Apaf-1 Deficiency and Neural Tube Closure Defects are Found in fog Mice von Honarpour, Narimon, Gilbert, Sandra L., Lahn, Bruce T., Wang, Xiaodong, Herz, Joachim

Volltext

Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF von Teerlink, John R, Diaz, Rafael, Felker, G Michael, McMurray, John J V, Metra, Marco, Solomon, Scott D, Legg, Jason C, Büchele, Gustavo, Varin, Claire, Kurtz, Christopher E, Malik, Fady I, Honarpour, Narimon

Volltext

Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial von Teerlink, John R, Prof, Felker, G Michael, Prof, McMurray, John J V, Prof, Solomon, Scott D, Prof, Adams, Kirkwood F, MD, Cleland, John G F, Prof, Ezekowitz, Justin A, MBBCh, Goudev, Assen, Prof, Macdonald, Peter, Prof, Metra, Marco, Prof, Mitrovic, Veselin, Prof, Ponikowski, Piotr, Prof, Serpytis, Pranas, Prof, Spinar, Jindrich, Prof, Tomcsányi, János, Prof, Vandekerckhove, Hans J, MD, Voors, Adriaan A, Prof, Monsalvo, Maria Laura, MD, Johnston, James, PhD, Malik, Fady I, MD, Honarpour, Narimon, MD

Volltext

Association between systolic ejection time and outcomes in heart failure by ejection fraction von Patel, Priyesh A., Ambrosy, Andrew P., Phelan, Matthew, Alenezi, Fawaz, Chiswell, Karen, Van Dyke, Melissa K., Tomfohr, Jennifer, Honarpour, Narimon, Velazquez, Eric J.

Volltext